Wyeth and Progenics Pharmaceuticals Inc. said Thursday that early results from a late-stage trial of their drug Relistor did not meet its goal in restoring gastrointestinal function following surgery to the intestine.
The study, in a condition known as post-operative ileus, failed to show a reduction in recovery time to a first bowel movement. The findings were not surprising as the companies in March said another late-stage trial for the condition also missed its goal.
The companies said that they would evaluate the data from both trials to determine how to proceed next in the indication.
Relistor won Food and Drug Administration approval in April to treat constipation caused by narcotic painkillers, known as opioid-induced constipation. The drug, which is given as an injection just under the skin, is set to launch in June.
Adolor Corp. and GlaxoSmithKline's Entereg, which was approved Tuesday, is the only drug on the market to treat post-operative ileus.
Wyeth and Progenics also said that a midstage trial of an oral formulation of Relistor to treat opioid-induced constipation "showed statistically significant activity." The companies expect results from a second trial in the coming months.
Shares of Wyeth closed Wednesday at $43.64, while shares of Progenics closed at $13.18. In premarket trading, Progenics shares fell 6 cents to $13.12.
Terms & Conditions
RSS Headlines
Fool UK